Navigation Links
Inovio Pharmaceuticals Reports 2012 Fourth Quarter and Year End Financial Results
Date:3/18/2013

as granted marketing approval in New Zealand for its high-dose plasmid therapy. The Company also reported that its new low-dose version of this therapy, LifeTide® SW 1.0, resulted in more live pigs per litter and higher birth and weaning weights.

About Inovio Pharmaceuticals, Inc. Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines are designed to provide universal cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with Inovio's proprietary electroporation delivery, have been shown in humans to generate best-in-class immune responses with a favorable safety profile. Inovio's clinical programs include Phase II studies for cervical dysplasia, leukemia and hepatitis C virus and Phase I studies for influenza and HIV. Partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, US Dept. of Homeland Security and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results d
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
2. Inovio Pharmaceuticals Reports 2012 First Quarter Financial Results
3. Inovio Pharmaceuticals to Present at SPI 2012
4. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
5. Inovio Pharmaceuticals to Present at JMP Investor Conference
6. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
7. Inovio Pharmaceuticals Inc. to Webcast, Live, at RetailInvestorConferences.com on August 2nd
8. Inovio Pharmaceuticals Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
9. Inovio Pharmaceuticals Reports 2012 Second Quarter Financial Results
10. Inovio Pharmaceuticals Takes Major Stride Toward Universal Influenza Vaccine
11. Inovio Pharmaceuticals Reports 2012 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... Z-Medica, a leading developer and marketer of ... line of products designed to meet the unique needs ... EMS 4x4 Dressing, QuikClot ® EMS TraumaPad ... all custom-designed to help responders stop bleeding fast and ... a hospital or trauma center. The line includes products ...
(Date:5/22/2013)... NEW ORLEANS , May 22, 2013 /PRNewswire/ ... period for commercially-insured patients with Type 2 diabetes, ... shown to improve health outcomes and can lead ... studies presented at the International Society for Pharmacoeconomics ... The two studies, sponsored by Valeritas, ...
(Date:5/22/2013)... -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) today announced ... at the following conferences. , Deutsche Bank 38th ... 29, 2013 , Presentation time: 12:00 p.m. P.T. ... Presentation date: Wednesday June 5, 2013 , Presentation time: ... live webcast and 30-day archive of these presentations will be ...
Breaking Medicine Technology:Z-Medica Launches New Line of Hemostatic Agents for use in Emergency Medical Services 2Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 2Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 3Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 4Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 5Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 6Avanir Pharmaceuticals to Participate in Two Upcoming Investor Conferences 2
... ~ Valopicitabine achieved both primary and secondary ... observed between,valopicitabine and ribavirin ~, CAMBRIDGE, Mass., ... today announced results from a phase II ... of,valopicitabine (NM283), Idenix's lead drug candidate for ...
... Demonstrates Significant,Additional Improvement for Patients on Pagoclone, ... Pharmaceuticals, Inc. today announced that results from ... in persistent,developmental stuttering will be presented today ... Clinical Drug Evaluation Unit (NCDEU), sponsored,by National ...
Cached Medicine Technology:Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 2Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 3Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 4Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 5Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 6Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 2Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 3Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 4Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 5Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 6Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 7Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 8Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 9
(Date:5/23/2013)... May 23, 2013 PhD Box ... the onset of the research process by offering assistance for ... to the repertoire of services that the company provides for ... behind launching a dedicated proposal writing service is that this ... new to the research process find it difficult to draft ...
(Date:5/23/2013)... Kitchen on Fire announces ... most advanced culinary technique series currently offered at this ... knowledge of how to purchase, butcher and cook the ... of organic, local ingredients. The new Intermediate Series consists ... each. The next series begins on Sunday, June 2, ...
(Date:5/23/2013)... Diego, CA (PRWEB) May 23, 2013 ... recently and they are now actively providing expert opinion ... Side Effects lawsuits. , According to court documents, ... in Illinois Southern District Court (case no. 3:2013cv50102) alleging ... Pradaxa, manufactured by Boehringer Ingelheim Pharmaceuticals, is mainly used ...
(Date:5/22/2013)... 2013 MileageAds.com, an American based full ... companies in the Stocks and Bonds Sector to display ... advertise with MileageAds will have the opportunity to take ... Stocks and bonds companies who accept Mileageads.com’s invitation will ... a specific, targeted audience on the internet ...
(Date:5/22/2013)... On May 16, 2012, LifeHealthPro reported that, ... concierge can help families negotiate lower costs for all aspects ... announces their top 3 reasons to hire a funeral ... U.S. having dropped 7.3 percent from $55,438 to $51,404 since ... 12.6% of an average U.S. households annual income. , Funeral ...
Breaking Medicine News(10 mins):Health News:PhD Box Unveils Proposal Writing Services for Research Scholars 2Health News:Kitchen on Fire Launches Intermediate Cooking Series, Advancing the Culinary Skills of Experienced Home Chefs 2Health News:Kitchen on Fire Launches Intermediate Cooking Series, Advancing the Culinary Skills of Experienced Home Chefs 3Health News:New Lawsuit on Pradaxa Brain Hemorrhage: Now, AttorneyOne Can Provide Advice 2Health News:Mileageads.com Ad Network Now Invites Companies in Stocks and Bonds Services Sector to Advertise on Their Ad Network 2Health News:Funeral Financials Announces Their Top 3 Reasons to Hire a Funeral Concierge 2Health News:Funeral Financials Announces Their Top 3 Reasons to Hire a Funeral Concierge 3
... , FRIDAY, Nov. 11 (HealthDay News) -- Certain types ... smokers who are generally anxious, according to a new study. ... to tune out anti-smoking videos that warn how smoking can ... harm others. "If you look at health messages, there ...
... Experts from The Neuroscience Institute at NYU Langone Medical ... discussions at the Society for Neuroscience 41st Annual Meeting ... meeting presents an opportunity for leading scientists from around ... for treating diseases and conditions of the brain," said ...
... Researchers at the University of Liverpool and the universities ... that cases of severe pneumonia among young children are ... cooking stoves. The research, published in the ... smoke from open fires and dirty cooking stoves, the ...
... scientists have developed a new technique using stem cells, ... disease. The technique could be developed for application in ... Thompson lead the research from the Florey Neuroscience Institutes ... the newly established Stem Cells Australia collaboration being launched ...
... THURSDAY, Nov. 10 (HealthDay News) -- Despite the known dangers ... but almost 70 percent want to quit, a new government ... Tim McAfee, director of the Office on Smoking and Health ... during a noon press conference Thursday. There was a ...
... (HealthDay News) -- Eating a high-fiber diet may reduce your ... cereal and whole grains, according to a new review. ... a total of nearly 2 million people. Compared with the ... increase in intake of total dietary fiber and cereal fiber ...
Cached Medicine News:Health News:Negative Anti-Smoking Ads Turn Off Anxious Viewers 2Health News:Woodsmoke from cooking fires linked to pneumonia 2Health News:Stem cell research hopes to repair brain damage of Parkinson's disease 2Health News:Stem cell research hopes to repair brain damage of Parkinson's disease 3Health News:Most Smokers Want to Quit, CDC Report Finds 2Health News:Most Smokers Want to Quit, CDC Report Finds 3Health News:Most Smokers Want to Quit, CDC Report Finds 4Health News:High-Fiber Diet May Help Thwart Colon Cancer 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: